Edition:
United States

KaloBios Pharmaceuticals Inc (KBIO.OQ)

KBIO.OQ on NASDAQ Stock Exchange Global Market

--USD
--
Change (% chg)

-- (--)
Prev Close
--
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

Select another date:

Mon, Sep 19 2016

BRIEF-Kalobios Pharma says appointed Morgan Lam as chief scientific officer

* Kalobios pharmaceuticals inc says appointed Morgan Lam, formerly chief operating officer of company, as company's chief scientific officer Source text for Eikon: (http://bit.ly/2cUjEff) Further company coverage:

BRIEF-KaloBios Pharmaceuticals announces Martin Shkreli'S sale of his stake in the company

* KaloBios announces Martin Shkreli'S sale of his stake in the company

BRIEF-Martin Shkreli dissolves stake in Kalobios Pharmaceuticals

* Martin Shkreli - sold all shares of Kalobios Pharmaceuticals common stock held on Aug 25, 2016 and Aug 26, 2016 in private transactions

BRIEF-Kalobios Pharmaceuticals files for non-timely 10-Q

* During first half of 2016, co's results of operations impacted by bankruptcy proceedings and operation as debtor-in-possession

BRIEF-KaloBios begins early stage study of leukemia treatment

* KaloBios announces first patient dosed in phase 1 study of Lenzilumab for the treatment of chronic myelomonocytic leukemia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Kalobios Pharmaceuticals says raised $12.2 mln in financing - SEC filing

* Says Raised $12.2 Mln In Equity And Other Financing - SEC filing

BRIEF-Nomis Bay Ltd reports 24.95 pct stake in Kalobios Pharmaceuticals as of June 30 - SEC filing

* Nomis Bay Ltd reports 24.95 percent stake in Kalobios Pharmaceuticals Inc as of June 30 - SEC filing Source text (http://bit.ly/29CFnCE) Further company coverage:

BRIEF-Dale Chappell reports 33.2 pct stake in Kalobios Pharmaceuticals

* Dale Chappell reports 33.2 percent stake in Kalobios Pharmaceuticals inc as of June 30 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Select another date: